Key Takeaways and Future Directions in Later Relapsed/Refractory MM
July 15th 2025Panelists discuss how talquetamab’s unique targeting mechanism offers significant advantages for patients with prior T-cell therapy exposure, whereas future research should focus on combination strategies and understanding primary resistance mechanisms.
Real-World Use, Outpatient Dosing and Transitions of Care in Academic and Community Settings
July 8th 2025Panelists discuss how successful outpatient bispecific therapy requires robust infrastructure, including 24-hour monitoring capabilities, emergency department coordination, and liberal use of supportive medications.
Talquetamab in R/R MM: Managing GPRC5D-direced AEs, Prophylaxis, and New Safety Signals
June 27th 2025Panelists discuss how cytokine release syndrome can be managed through early intervention with tocilizumab and steroids, and emphasize the importance of patient and staff education for safe outpatient administration.
Safety Updates and Concluding Thoughts From Extended Follow-Up of MonumenTAL-1
June 27th 2025Panelists discuss how talquetamab shows a more favorable safety profile with significantly lower high-grade infection rates compared with B-cell maturation antigen (BCMA)–directed bispecifics, although a new cerebellar toxicity signal requires monitoring.
MonumenTAL-1: Implications of Talquetamab, Prior TCR, and Sequencing for R/R MM
June 20th 2025Panelists discuss how talquetamab demonstrates remarkable efficacy in patients previously exposed to T-cell redirecting (TCR) therapies, with response rates and duration comparable to treatment-naive patients.
ASCO 2025: MonumenTAL-1 Extended Follow-Up for Talquetamab in R/R MM
June 13th 2025Panelists discuss how talquetamab targets GPRC5D, which is heavily expressed on malignant plasma cells but not normal B cells, potentially explaining lower infection rates compared with B-cell maturation antigen (BCMA)–targeted therapies.